Leverage The Most Trusted FDA Advertising Compliance Experts in the World

The FDA’s Office of Prescription Drug Promotion (OPDP) closely monitors how companies advertise and promote prescription drugs. Each year, the agency issues Untitled Letters and Warning Letters for violations such as misleading or non-substantiated claims, omission of required safety information, or promotion of unapproved uses. These enforcement actions signal that your promotional materials may be putting patients at risk and your company at odds with regulators.

FDA Advertising Compliance Matters Now More Than Ever 

The stakes are higher than ever. With FDA’s recent crackdown on deceptive drug advertising, enforcement has become more aggressive and far-reaching. Untitled and Warning Letters can require immediate campaign corrections, force promotional activities to halt, and trigger costly fines or long-term reputational damage. Many companies do not realize their materials are non-compliant until they are already facing regulatory action, when remediation is both urgent and expensive. Proactively ensuring compliance before materials go to market is now essential to protect your brand, mitigate risk, and stay ahead of shifting FDA priorities.

Working with an experienced regulatory consultant can make the difference between costly missteps and long-term success. Experts who understand FDA requirements and evolving enforcement trends can help you build compliant processes, review promotional content with precision, and safeguard your organization against regulatory setbacks.

Don’t navigate FDA scrutiny alone. Our experts help you ensure compliance, avoid enforcement letters, and protect your brand in today’s heightened regulatory environment.